SomaLogic Press Release

(BOULDER, CO) SomaLogic, Inc., a privately-held proteomics company, announced today that David M. Lawrence, M.D. has been named an advisor to the company's board of directors. As an advisor to the seven-person board, Dr. Lawrence will support SomaLogic's efforts to develop strategic partnerships with researchers and will help launch the company's aptamer-based proteomic technology into the worldwide clinical diagnostics market.

"David possesses a lifetime of experience within the health care delivery arena," stated Dr. Larry Gold, SomaLogic's Chairman of the Board and Chief Scientific Officer. "He also thoroughly understands the goals and objectives of SomaLogic in addition to the global benefits of our technology. His thought-provoking book, "From Chaos to Care: The Promise of Team-Based Medicine" describes both the strengths and the shortcomings of healthcare systems in developed countries, and provides a bold, clear prescription for how to improve these systems. David's vision for the role of diagnostics is consistent with SomaLogic's world view. We are confident that this shared understanding, coupled with his vast experience and knowledge of the field, will provide SomaLogic with both partnership opportunities and a chance to solve some of the more difficult issues we all face."

"SomaLogic is a well-respected company at the forefront of a very exciting science," added Dr. Lawrence. "The fields of gene expression, genomics, and proteomics are in their infancy, but the clinical implications of these technologies are boundless. I am thrilled to be involved with a company such as SomaLogic that is developing a revolutionary technology that will greatly advance and transform the screening, diagnosis, and treatment of disease. Companies such as SomaLogic will provide the information and insights that physicians need to practice evidence-based medicine, a critical approach for improving healthcare systems."

In addition to advising the board of SomaLogic, Dr. Lawrence currently serves on the boards of directors of Agilent Technologies, Pacific Gas and Electric Company, Raffles Medical Group of Singapore, The Rockefeller Foundation and the RAND Health Advisory Board. He is also Board Certified in General Preventive Medicine and is a member of the Alpha Omega Alpha Medical Honorary Society and the Institute of Medicine within the National Academy of Sciences.

From 1992 to 2002, Dr. Lawrence served as Chief Executive Officer and Chairman of the Board of the Oakland, California-based Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals (KFHP/KFH). He joined Kaiser Permanente in 1981 as the Vice President and Area Medical Director for Northwest Permanente in Portland, Oregon. Throughout the next 10 years, he held numerous senior-level positions with the company including Vice Chairman and Chief Operating Officer, Senior Vice President and Regional Manager for Northern California and Vice President and Regional Manager in Colorado.

Before joining KFHP/KFH, Dr. Lawrence was also Health Officer and Director of Human Services in Multnomah County, Oregon, and the Director of MEDEX at the School of Public Health and Community Medicine at the University of Washington. In addition, he served as an advisor to the Ministry of Health of Chile and as a Peace Corps physician in the Dominican Republic and in Washington, D.C.

Dr. Lawrence holds a bachelor of arts degree from Amherst College, a medical degree from the University of Kentucky, and a master of public health degree from the University of Washington. During his distinguished career, Dr. Lawrence has also been recognized as the Outstanding Alumnus of the School of Public Health and Community Medicine at the University of Washington as well as the Outstanding Alumnus at the College of Medicine at the University of Kentucky. He is a member of the Hall of Distinguished Alumni at the University of Kentucky and holds honorary doctorate degrees from Amherst College, Colgate University, and the University of Kentucky.

Contact:
SomaLogic
Beth Perez
pr-ir@somalogic.com

Except for the historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements include SomaLogic's prospects for favorable growth and performance. The statements made by SomaLogic, Inc. are based on management's present expectations and actual results may differ from the results indicated or otherwise implied by such forward-looking statements due to certain risks and uncertainties including, but not limited to, our ability to secure funding to execute our business plan, our ability to gain market share by establishing the effectiveness of our products, the intense competition in research proteomics and commercial diagnostics, and general industry or business trends or events. These risk factors may not be an all-inclusive enumeration of the business risks faced by SomaLogic, Inc. These statements made by the management of SomaLogic, Inc. and summarized above represent their views as of the date of this press release, and it should not be assumed that the statements made herein remain accurate as of any future date. SomaLogic, Inc. does not presently intend to update these statements and undertakes no duty to any person to effect any such update under any circumstances.